NEW YORK (TheStreet) -- I have been talking about, writing about and, most important, investing in stocks for my clients and myself for a long time. You do not have to be a scientist or doctor to invest in scientific or medical progress.
Of the nearly 3,800 stocks I cover in my database, most do not get white-hot overnight. Neither do they lose all their value overnight.
So I look for industries first, then companies within those industries when I am selecting investments. I use the database that I created to select the Best Stocks Now.
Data from Best Stocks Now App
I didn't hear about ANAC from a televised talking head. Nor did I read about it in the Wall Street Journal or Barron's. I found it while scouring the database that I created.
ANAC is in the atopic dermatitis business. Eczema. One of its products is getting some good results and some even say it could be a new standard of treatment for this disease. But just because something is a good company in a good industry with a good even great product, it does not necessarily mean it is a good stock.
ANAC became public in 2010 at $5 per share. I noticed it three months ago when it hit #23 based on my proprietary grading system. Looking at the chart, we see it has done a powerful saucer pattern from April until Mid-August of this year when ANAC broke out and rose up the ranks in my database.